📊 RXRX Key Takeaways
Is Recursion Pharmaceuticals, Inc.. (RXRX) a Good Investment?
Recursion is deeply unprofitable with operating losses of $648.1M against $74.7M revenue, indicating a fundamentally unsustainable business model. While the company maintains a strong balance sheet with $743.3M cash and minimal debt, it burns $378.3M annually in free cash flow with no clear path to profitability, constraining the 2-year cash runway.
Why Buy Recursion Pharmaceuticals, Inc.. Stock? RXRX Key Strengths
- Strong balance sheet with $743.3M cash equivalents and minimal debt ($9.6M long-term debt)
- Excellent liquidity position with 5.50x current ratio and 0.01x debt-to-equity ratio
- Revenue growth of 26.9% YoY demonstrating commercial traction
- Low capital expenditure requirements ($6.5M) relative to asset base
RXRX Stock Risks: Recursion Pharmaceuticals, Inc.. Investment Risks
- Massive operating losses of -$648.1M with -867.9% operating margin indicating unsustainable cost structure
- Negative free cash flow of -$378.3M annually with cash burn rate exceeding revenue by 5x
- Net losses worsening 39.1% YoY despite revenue growth indicating deteriorating unit economics
- Approximate 2-year cash runway at current burn rate necessitating significant cost reduction or additional capital
- No identified path to profitability or inflection point in near-term financial projections
- Dependency on continued capital markets access to sustain operations
Key Metrics to Watch
- Monthly operating cash flow burn rate and quarterly trends in cash position
- Operating expense ratio relative to revenue growth to assess path to unit profitability
- Gross margin expansion and operating leverage improvement
- Capital raise activity and timing of additional financing rounds
Recursion Pharmaceuticals, Inc.. (RXRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.50x current ratio provides a solid financial cushion.
RXRX Profit Margin, ROE & Profitability Analysis
RXRX vs Healthcare Sector: How Recursion Pharmaceuticals, Inc.. Compares
How Recursion Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Recursion Pharmaceuticals, Inc.. Stock Overvalued? RXRX Valuation Analysis 2026
Based on fundamental analysis, Recursion Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Recursion Pharmaceuticals, Inc.. Balance Sheet: RXRX Debt, Cash & Liquidity
RXRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Recursion Pharmaceuticals, Inc..'s revenue has grown significantly by 634% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.58 indicates the company is currently unprofitable.
RXRX Revenue Growth, EPS Growth & YoY Performance
RXRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $5.2M | -$95.8M | $-0.34 |
| Q2 2025 | $14.4M | -$97.5M | $-0.40 |
| Q1 2025 | $13.8M | -$91.4M | $-0.39 |
| Q3 2024 | $10.5M | -$93.0M | $-0.34 |
| Q2 2024 | $11.0M | -$76.7M | $-0.38 |
| Q1 2024 | $12.1M | -$65.3M | $-0.34 |
| Q3 2023 | $10.5M | -$60.4M | $-0.35 |
| Q2 2023 | $7.7M | -$65.6M | $-0.38 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Recursion Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
RXRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Recursion Pharmaceuticals, Inc.. (CIK: 0001601830)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 8, 2026 | 4 | xslF345X06/wk-form4_1775681908.xml | View → |
| Apr 8, 2026 | 4 | xslF345X06/wk-form4_1775681902.xml | View → |
| Apr 8, 2026 | 4 | xslF345X06/wk-form4_1775681895.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/wk-form4_1775163383.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/wk-form4_1775163374.xml | View → |
❓ Frequently Asked Questions about RXRX
What is the AI rating for RXRX?
Recursion Pharmaceuticals, Inc.. (RXRX) has an AI rating of SELL with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RXRX's key strengths?
Claude: Strong balance sheet with $743.3M cash equivalents and minimal debt ($9.6M long-term debt). Excellent liquidity position with 5.50x current ratio and 0.01x debt-to-equity ratio.
What are the risks of investing in RXRX?
Claude: Massive operating losses of -$648.1M with -867.9% operating margin indicating unsustainable cost structure. Negative free cash flow of -$378.3M annually with cash burn rate exceeding revenue by 5x.
What is RXRX's revenue and growth?
Recursion Pharmaceuticals, Inc.. reported revenue of $74.7M.
Does RXRX pay dividends?
Recursion Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find RXRX SEC filings?
Official SEC filings for Recursion Pharmaceuticals, Inc.. (CIK: 0001601830) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RXRX's EPS?
Recursion Pharmaceuticals, Inc.. has a diluted EPS of $-1.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RXRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Recursion Pharmaceuticals, Inc.. has a SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RXRX stock overvalued or undervalued?
Valuation metrics for RXRX: ROE of -57.0% (sector avg: 15%), net margin of -863.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RXRX stock in 2026?
Our dual AI analysis gives Recursion Pharmaceuticals, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RXRX's free cash flow?
Recursion Pharmaceuticals, Inc..'s operating cash flow is $-371.8M, with capital expenditures of $6.5M. FCF margin is -506.5%.
How does RXRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -863.4% (avg: 12%), ROE -57.0% (avg: 15%), current ratio 5.50 (avg: 2).